NCT/Study#
NCT06774963 /
LNCB74-101
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY FOR LNCB74, A B7-H4 TARGETED ANTIBODY DRUG CONJUGATE, AS MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS Sponsor Protocol
DISEASE GROUP:
Biliary Track, Endometrial, Breast, Ovarian, NSCLC
current phase:
Phase I
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
